The Nuclear Receptor Superfamily

Kush Dalal, Ravi Munuganti, Hélène Morin, Nada Lallous, Paul S. Rennie, Artem Cherkasov, Dalal, Kush, Munuganti, Ravi, Morin, Hélène, Lallous, Nada, Rennie, Paul S., Cherkasov, Artem

The androgen receptor (AR) is an important regulator of genes responsible for the development and recurrence of prostate cancer. Current therapies for this disease rely on small-molecule inhibitors that block the transcriptional activity of the AR. Recently, major advances in the development of novel AR inhibitors resulted from X-ray crystallographic information on the receptor and utilization of in silico drug design synergized with rigorous experimental testing.Herein, we describe a drug-discovery pipeline for in silico screening for small molecules that target an allosteric region on the AR termed the binding-function 3 (BF3) site. Following the identification of potential candidates, the compounds are tested in cell culture and biochemical assays for their ability to interact with and inhibit the AR. The described pipeline is readily accessible and could be applied in drug design efforts toward any surface-exposed region on the AR or other related steroid nuclear receptor.